Live viral vaccines in patients with partial DiGeorge syndrome: clinical experience and cellular immunity

Partial DiGeorge syndrome (pDGS) is an inherited primary immunodeficiency syndrome (incidence, 1:3000 live births) primarily affecting cellular immune function; partial, infers thymic hypoplasia with detectable circulating T-lymphocytes and adequate function. No guidelines exist regarding the recomm...

Full description

Saved in:
Bibliographic Details
Published in:Clinical immunology (Orlando, Fla.) Fla.), 2004-07, Vol.112 (1), p.106-112
Main Authors: Moylett, Edina H, Wasan, Anita N, Noroski, Lenora M, Shearer, William T
Format: Article
Language:English
Subjects:
Adolescent
Biological and medical sciences
Cellular immunity
Child
Child, Preschool
Cohort Studies
DiGeorge syndrome
DiGeorge Syndrome - immunology
DiGeorge Syndrome - virology
Female
Flow Cytometry
Fundamental and applied biological sciences. Psychology
Fundamental immunology
Humans
Immunization - adverse effects
Immunocompromised
Immunopathology
Immunophenotyping
Infant
Live viral vaccines
Lymphocyte Activation
Male
Medical sciences
MMR vaccine
Partial DiGeorge syndrome
Phytohemagglutinin
Retrospective Studies
Statistics, Nonparametric
Surveys and Questionnaires
T-Lymphocytes - immunology
T-Lymphocytes - virology
Varicella vaccine
Viral Vaccines - adverse effects
Viral Vaccines - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Partial DiGeorge syndrome (pDGS) is an inherited primary immunodeficiency syndrome (incidence, 1:3000 live births) primarily affecting cellular immune function; partial, infers thymic hypoplasia with detectable circulating T-lymphocytes and adequate function. No guidelines exist regarding the recommendations for use of live viral vaccines (LVVs) in this extensive population of pediatric patients. We reviewed the experience with live viral vaccines in our cohort of patients with pDGS. Of 53 patients, 25 (47%) had received a live viral vaccine. No significant adverse events were recorded in association with administration of live viral vaccines. There was no statistically significant difference between cellular immune function at initial presentation between those patients that received live viral vaccines and those that did not. Adequate cellular immune function was documented for 15 of the 25 LVV recipients at the time of vaccine administration without significant change from baseline. These observations suggest that live viral vaccines appear safe in patients with pDGS and stable immune function.
ISSN:1521-6616
1521-7035
DOI:10.1016/j.clim.2004.02.008